Carvykti(ciltacabtagene autoleucel, cilta-cel )西达基奥仑赛的说明 又名为JNJ-4528/LCAR-B38M,是一种具有差异性结构的嵌合抗原受体T细胞(CAR-T)细胞疗法,包含一个4-1BB共刺激结构域,及两个靶向B细胞成熟抗原(BCMA)的抗体结构域。BCMA是一种在骨髓瘤细胞上高度表达的蛋白,是治疗多发性骨髓瘤的理想靶点。
However, the comprehensive chronological pathophysiologic landscape of CRS upon CAR-T therapy hasn’t yet been fully elucidated. Ciltacabtagene autoleucel (Cilta-cel, previously known as LCAR-B38M) is a biepitopic CAR-T product targeting BCMA antigen, and has achieved remarkable success in the...
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk...
最近,强生旗下杨森制药宣布,已启动向美国食品(http://www.maoyihang.com/sell/l_32/)和药物管理局(FDA)滚动提交ciltacabtagene autoleucel(cilta-cel)的生物制品许可申请(BLA)。 关于cilta-cel cilta-cel是一款在研的B细胞成熟抗原(BCMA)导向的嵌合抗原受体T细胞(CAR-T)疗法,用于治疗复发或难治性多发性骨髓...
12Legend Biotech Business Wire. Das China Center for Drug Evaluation, National Medical Products Administration hat den Breakthrough-Therapy-Status für die BCMA CAR-T-Zelltherapie Ciltacabtagene Autoleucel (Cilta-cel, LCAR-B38M CAR-T-Zellen) empfohlen. Verfügbar unter:https://www.businesswire...
Carvykti(ciltacabtagene autoleucel,cilta-cel)西达基奥仑赛,又名为JNJ-4528/LCAR-B38M,是一种具有差异性结构的嵌合抗原受体T细胞(CAR-T)细胞疗法,包含一个4-1BB共刺激结构域,及两个靶向B细胞成熟抗原(BCMA)的抗体结构域。BCMA是一种在骨髓瘤细胞上高度表达的蛋白,是治疗多发性骨髓瘤的理想靶点。